Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a 24-Hour liquid diet make GLP-1 users safer for surgery?

NCT ID NCT06839248

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a 24-hour clear liquid diet reduces leftover stomach contents in people taking weekly GLP-1 medications (like Ozempic). These drugs can slow digestion, raising the risk of stomach contents entering the lungs during procedures. Researchers will compare the liquid diet to standard fasting rules in 154 adults using a stomach ultrasound to check results.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
24-hour clear liquid diet
What this could lead to
If successful, this could lead to better fasting guidelines for patients on GLP-1 medications, reducing the risk of stomach contents entering the lungs during surgery.
What could go wrong
This is a small, early-stage trial (154 participants) testing a dietary change, not a new drug. Results may not apply to all patients or settings, and the intervention may be hard to follow.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 154 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years old at enrolment. * Have regularly administered any type of once-weekly GLP-1 RA medication for a period of at least one month prior to randomisation. * If allocated to follow standard fasting guidelines, willing to adhere to ASA and ANZCA preoperative fasting requirements. This requires participants to only consume clear liquids up to 2 hours, a light or low calorific meal up to 6 hours, and fasting from fried foods, fatty foods, or meat for at least 8 hours prior to the trial visit. * If allocated to follow a 24-hour clear liquid diet, willing to adhere to nothing-by-mouth (NPO) for solids and last intake of clear liquids no less than 2 hours prior to the trial visit. * Provide a signed and dated informed consent form for study participation in line with the requirements of the human research ethics committee (HREC) of the study site. Exclusion Criteria: Participants meeting any of the following criteria, indicative of abnormal anatomy and not validated by gastric ultrasound, will be excluded from this trial: * Has a recent history of gastrointestinal bleed within the previous 1 month from enrolment. * Has a history of previous lower oesophageal or gastric surgery. * Has a known abnormal upper gastrointestinal anatomy, including hiatus hernia or gastric tumours. In addition, participants meeting any the of following criteria will be excluded from this trial: * Participant reports having been previously diagnosed with a clinically significant gastric emptying abnormality such as gastroparesis. * Participant reports concomitant use of insulin. * Unable to assume the right lateral decubitus position required for gastric ultrasound assessment. * Participant has difficulty fully understanding PICF or study materials due to a primary language other than English.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary aspiration of gastric contents are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aspiration pneumonia Respiratory Aspiration of Gastric Contents

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Melbourne Gastro Oesophageal Surgery (MGOS)

    RECRUITING

    Melbourne, Victoria, 3002, Australia

  • St Vincent's Hospital Melbourne

    RECRUITING

    Melbourne, Victoria, 3065, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.